CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
designed to evaluate the efficacy, safety, and tolerability of two doses of CT1812 compared to placebo in participants diagnosed with early Alzheimer's...
Phase 2
Palo Alto, California, United States and 29 other locations
This study is designed to evaluate safety and efficacy of fosgonimeton (ATH-1017) in the treatment of mild to moderate Alzheimer's disease...
Phase 2, Phase 3
Lafayette, California, United States of America and 89 other locations
progression of AD, as compared to no stimulation (OFF), by measuring baseline (pre-implantation) to 12-month change in the integrated Alzheimer's...
Stanford, California, United States and 20 other locations
The investigators will study performance on computerized cognitive tasks in healthy participants of different ages to gather normative data for newly...
Berkeley, California, United States
is superior to placebo on change from baseline of the Preclinical Alzheimer Cognitive Composite 5 (PACC5) at 216 weeks of treatment (A45 Tri...
Phase 3
San Francisco, California, United States and 117 other locations
versus (vs) placebo on the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) up to Week 80 in study participants with prodromal or mild Alzheimer's...
Phase 2
Palo Alto, California, United States and 102 other locations
This study will be conducted to evaluate the efficacy of lecanemab in participants with early Alzheimer's disease (EAD) by determin...
Phase 3
San Francisco, California, United States of America and 246 other locations
The objective of this study is to determine the safety and tolerability of fosgonimeton (ATH-1017) in subjects with mild to moderate Alzheimer's...
Phase 2, Phase 3
Lafayette, California, United States of America and 75 other locations
study is to assess the effectiveness, safety, and tolerability of BMS-986446 an Anti-MTBR Tau Monoclonal Antibody in participants with Early Alzheimer's...
Phase 2
San Francisco, California, United States and 202 other locations
This AR1001-ADP3-US01 protocol is a double-blind, randomized, placebo-controlled, multi- center, parallel-group comparison pivotal Phase 3 study to e...
Phase 3
Burlingame, California, United States and 99 other locations
Clinical trials
Research sites
Resources
Legal